Human LILRB4 (ILT-3) knockout A549 cell line
Be the first to review this product! Submit a review
|
(0 Publication)
LILRB4 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon 2 and 52 bp deletion in exon 2.
View Alternative Names
CD85 antigen-like family member K, CD85k, HM18, ILT-3, Immunoglobulin-like transcript 3, LILRB4, LIR-5, LIRB4_HUMAN, Leukocyte immunoglobulin like receptor subfamily B (with TM and ITIM domains) member 4, Leukocyte immunoglobulin-like receptor 5, Leukocyte immunoglobulin-like receptor subfamily B member 4, Monocyte inhibitory receptor HM18
- Cell Culture
Unknown
Cell Culture - Human LILRB4 (ILT-3) knockout A549 cell line (AB266985)
Representative images of LILRB4 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.
- Sanger seq
Unknown
Sanger Sequencing - Human LILRB4 (ILT-3) knockout A549 cell line (AB266985)
Allele-1 : 52 bp deletion in exon2
- Sanger seq
Unknown
Sanger Sequencing - Human LILRB4 (ILT-3) knockout A549 cell line (AB266985)
Allele-2 : 4 bp deletion in exon 2.
Product details
Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium
F-12K + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ILT-3 acts as an inhibitory receptor that modulates immune responses. It is often linked with the control of T cell activation and the maintenance of immune tolerance. ILT-3 does not form part of a larger protein complex. Its inhibitory function helps in preventing overactivation of the immune system by modulating the signaling pathways necessary for immune response. This modulation occurs through ITIM (Immunoreceptor Tyrosine-based Inhibitory Motif) domains that recruit phosphatases helping in dephosphorylating key signaling proteins and aiding in downregulation of immune cell activities.
Pathways
The ILT-3 protein is involved in important immune regulatory pathways contributing significantly to the immune checkpoint pathway. It interacts with other immunoglobulin-like receptors and is known to influence pathways involving PD-1 (Programmed cell death protein 1) and CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4). By affecting these pathways ILT-3 serves as a checkpoint that ensures immune homeostasis prevents excess inflammation and influences the balance between immune activation and suppression within the body.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Target data
Complementary Products
![Flow Cytometry - Anti-ILT-3 antibody [EPR22030] (AB224716)](https://content.abcam.com/products/images/ilt-3-antibody-epr22030-ab224716--flow-cytometry-img105668.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com